No abstract

No abstract

We have compared four cell-based tumour vaccine strathe two latter vaccines promoted antitumour activity, tegies in prevention experiments using the B16-F10 melawhereas the vaccines consisting of B7.1-expressing noma model. Two of these are thought to favour the direct tumour cells or the hybrid vaccine failed to provide any antigen presentation pathway (B16-F10 expressing B7.1 antitumour activity. Recently human trials have comand hybrids made between B16-F10 cells and menced using transfection of the B7.1 molecule, as well macrophages) and the other two strategies are thought to as employing the hybrid technology to make tumour-B cell act by an indirect pathway of presentation (allogeneic hybrids or tumour and dendritic cell hybrids. Our results tumour cells and autologous tumour cells combined with a suggest that these approaches could be disappointing in powerful adjuvant (Provax-IDEC Pharmaceuticals)). Only the clinics if not optimised.